Mankind Pharma IPO : Should you apply or avoid

Mankind Pharma IPO. This IPO has been making waves in the market and has garnered a lot of attention from investors. In this article, we will provide you with a detailed analysis of the Mankind Pharma IPO, including its history, business model, financials, and future prospects.

Mankind Pharma IPO Details

Mankind Pharma IPO Dates	25 – 27 April 2023
Mankind Pharma IPO Price	INR 1,026 – 1,080 per share
Fresh issue	Nil
Offer For Sale	4,00,58,844 shares (INR 4,110.04 – 4,326.36 crore)
Total IPO size	INR 4,300 crore
Minimum bid (lot size)	13 shares (INR 14,040)
Face Value	INR 1 per share
Retail Allocation	35%
Listing On	BSE, NSE

Introduction

Mankind Pharma is a leading pharmaceutical company that was founded in 1995. The company has a strong presence in the Indian pharmaceutical market and is known for its affordable and high-quality products. The company is now planning to go public with its IPO.

Business Model

Mankind Pharma operates in various therapeutic areas, including gastroenterology, cardiology, neurology, and more. The company has a diverse product portfolio that includes prescription drugs, over-the-counter products, and medical devices.It has over 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among them.

The company’s business model is focused on innovation and R&D. Mankind Pharma has invested heavily in its R&D capabilities, which has helped the company to develop new and innovative products. The company has a strong focus on quality control, and all of its products undergo rigorous testing before they are launched in the market.

Financials

Mankind Pharma has shown strong financial performance over the years. The company has grown at a CAGR of 21% over the last 5 years, with a revenue of INR 6,039 crores in FY 2021. The company’s net profit in FY 2021 was INR 1,337 crores, which is a 27% increase from the previous year.

Mankind Pharma Financial Performance

	FY 2020	FY 2021	FY 2022
Revenue	5,865.2	6,214.4	7,781.6
Expenses	4,549.5	4,705.5	6,017.4
Net income	1,056.2	1,293.0	1,453.0
PAT Margin (%)	18.0	20.8	18.7

Future Prospects

Mankind Pharma has a strong growth outlook. The company has a robust pipeline of products in various therapeutic areas, which are expected to drive growth in the coming years. The company’s focus on innovation and R&D is expected to help it stay ahead of the competition and maintain its market share.

The IPO is expected to help Mankind Pharma raise funds to fuel its growth plans. The funds raised will be used to invest in R&D, expand the company’s manufacturing capabilities, and expand its market presence.

•   ›  Mankind Pharma IPO DRHP

Objects of the IPO

All of the offer proceeds will be received by the selling shareholders in proportion to the offered shares that each selling shareholder sold as part of the offer; the company will not receive any of the offer proceeds.

Mankind Pharma IPO Tentative Timetable

Mankind Pharma IPO opens on Apr 21, 2023, and closes on Apr 25, 2023.

Event	Tentative Date
Opening Date	Apr 21, 2023
Closing Date	Apr 25, 2023
Basis of Allotment	Apr 28, 2023
Initiation of Refunds	May 2, 2023
Credit of Shares to Demat	May 3, 2023
Listing Date	May 4, 2023
UPI Mandate Confirmation Cut-Off Time	5.00 PM on the issue closing day

Conclusion

In conclusion, Mankind Pharma is a leading pharmaceutical company in India with a strong business model and a focus on innovation and R&D. The company has shown strong financial performance over the years and has a bright future ahead. The IPO is expected to help the company raise funds to fuel its growth plans and expand its market presence. We hope this article has provided you with a comprehensive understanding of the Mankind Pharma IPO and its future prospects.